US Stock Insider Trading | Rapid Micro disclosed 1 insider transaction on March 2

K-LinePoet · 2026-03-11T17:57:18+00:00

On March 2, 2026, Rapid Micro disclosed an insider transaction, with Director Ricciardi Natale S purchasing 842 shares on February 27 for a total of $631.50. Recent transactions also include buy and sell activities by other executives and major shareholders, reflecting active trading within the company. Rapid Micro is a company that provides life science technology solutions, focusing on the manufacturing and quality control of biopharmaceuticals and medical products.

K-LinePoet

2026-03-11 17:57:18

Abstract generation in progress

On March 2, 2026, Rapid Micro (RPID) disclosed a recent insider transaction. Director RICCIARDI NATALE S purchased 842 shares on February 27, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Director	RICCIARDI NATALE S	February 27, 2026	Buy	842	0.75	631.50
February 20, 2026	Executive	WIRTJES SEAN M	February 20, 2026	Sell	17,300	3.92	67,700
February 20, 2026	Director	Spignesi Robert G. Jr.	February 19, 2026	Sell	38,300	3.89	148,900
February 20, 2026	Executive	Wilson John J. Addington	February 20, 2026	Sell	5,403	3.92	21,200
February 10, 2026	Director	Spignesi Robert G. Jr.	February 9, 2026	Sell	12,800	3.78	48,600
February 10, 2026	Executive	Wilson John J. Addington	February 9, 2026	Sell	4,610	3.78	17,400
February 10, 2026	Executive	WIRTJES SEAN M	February 9, 2026	Sell	6,027	3.78	22,800
February 6, 2026	Shareholder with >10% stake	Longitude Capital Partners II, LLC	February 4, 2026	Sell	49,000	3.88	190,100
February 3, 2026	Shareholder with >10% stake	Longitude Capital Partners II, LLC	January 23, 2026	Buy	629,000	0.05	31,500
February 3, 2026	Shareholder with >10% stake	Longitude Capital Partners II, LLC	February 2, 2026	Sell	27,500	4.25	116,800

【Company Profile】

Rapid Micro Biosystems, Inc. was incorporated on December 29, 2006, under Delaware law. The company is an innovative life sciences technology firm providing automation solutions to facilitate efficient manufacturing and rapid, safe release of healthcare products such as biopharmaceuticals, vaccines, cell and gene therapies, and sterile injectables. The company develops, manufactures, and sells the Growth Direct system’s proprietary consumables, Laboratory Information Management System (“LIMS”) connection software, and services to address rapid microbial testing for quality control in the manufacturing of pharmaceuticals, medical devices, and personal care products. Currently, the company sells its products to customers in North America, Europe, and Asia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.